Capillary Electrophoresis Evaluated for Hemoglobinopathy Testing
|
By LabMedica International staff writers Posted on 25 May 2015 |

Image: The Minicap Flex Piercing capillary zone electrophoresis system (Photo courtesy of Sebia).
The detection of structural hemoglobin (Hb) variants and thalassemia has become increasingly important in clinical laboratories of all countries with a large influx of immigrants over the past 10 years.
Guidelines for hemoglobinopathy screening not only recommend the use of quantitative techniques for thalassemia detection, they also stress the use of a confirmatory method when an Hb variant is detected. In an ideal setting, both techniques can be met by a combination of high-performance liquid chromatography (HPLC) and capillary zone electrophoresis (CZE).
Scientists at the University Hospital Leuven (Belgium) and their colleagues evaluated a suitable stand-alone method for hemoglobinopathy screening of approximately 50 clinical samples a week. The studied the analytical performance of a CZE and set up a comparison with two well-established HPLC methods.
Capillary zone electrophoresis was performed using the Minicap Flex Piercing CZE system (Sebia; Norcross, GA, USA). The instrument is equipped to resuspend, lyse, separate, and analyze whole blood samples for variants collected in ethylenediaminetetraacetic acid (EDTA) tubes. The lysed red cells are electrophoresed in alkaline buffer (pH 9.4) allowing separation to be directed by pH and endosmosis. Detection of eluting hemoglobin species is accomplished using the change in absorbance at 415 nm. CZE does not require daily calibration, but normal HbA and HbA2 migration controls are analyzed daily through each capillary before additional quality control (QC), or patient samples are run to ensure proper charge and function of both capillaries. The two well-established HPLC methods were the Bio-Rad Variant Classic and the Bio-Rad D-10 instruments (Bio-Rad Laboratories; Hercules, CA, USA).
The analytical performance was acceptable for the determination of HbA, HbA2, HbS, and HbF, with an imprecision equal to or less than 2.0%. Method comparison showed a linear correlation for HbA2, HbF, and HbS measurements. Clinical concordance was acceptable when comparing CZE and HPLC. Hb variant presumptive identification was evaluated by analyzing seven samples with confirmed heterogeneous or homogeneous presence of Hb variants: two HbC, one HbD, one HbE and HbA2'. One sample was compound heterogeneous for HbS and HbC. On the Minicap Flex Piercing, a minimal overlap between HbC and HbA2 was found.
The authors concluded that as HPLC methods have the advantage of a great precision in detection of a large number of variants, it has the disadvantage of a complex elution pattern that may be difficult to interpret for many routine chemistry laboratories. The Minicap Flex Piercing showed similar analytical performance compared to previous published work using CZE. As for HPLC, CZE gives only a provisional identification of variant hemoglobins, and confirmation by an alternative method based on a different principle is needed. The study was published in the June 2015 issue of the International Journal of Laboratory Hematology.
Related Links:
University Hospital Leuven
Sebia
Bio-Rad Laboratories
Guidelines for hemoglobinopathy screening not only recommend the use of quantitative techniques for thalassemia detection, they also stress the use of a confirmatory method when an Hb variant is detected. In an ideal setting, both techniques can be met by a combination of high-performance liquid chromatography (HPLC) and capillary zone electrophoresis (CZE).
Scientists at the University Hospital Leuven (Belgium) and their colleagues evaluated a suitable stand-alone method for hemoglobinopathy screening of approximately 50 clinical samples a week. The studied the analytical performance of a CZE and set up a comparison with two well-established HPLC methods.
Capillary zone electrophoresis was performed using the Minicap Flex Piercing CZE system (Sebia; Norcross, GA, USA). The instrument is equipped to resuspend, lyse, separate, and analyze whole blood samples for variants collected in ethylenediaminetetraacetic acid (EDTA) tubes. The lysed red cells are electrophoresed in alkaline buffer (pH 9.4) allowing separation to be directed by pH and endosmosis. Detection of eluting hemoglobin species is accomplished using the change in absorbance at 415 nm. CZE does not require daily calibration, but normal HbA and HbA2 migration controls are analyzed daily through each capillary before additional quality control (QC), or patient samples are run to ensure proper charge and function of both capillaries. The two well-established HPLC methods were the Bio-Rad Variant Classic and the Bio-Rad D-10 instruments (Bio-Rad Laboratories; Hercules, CA, USA).
The analytical performance was acceptable for the determination of HbA, HbA2, HbS, and HbF, with an imprecision equal to or less than 2.0%. Method comparison showed a linear correlation for HbA2, HbF, and HbS measurements. Clinical concordance was acceptable when comparing CZE and HPLC. Hb variant presumptive identification was evaluated by analyzing seven samples with confirmed heterogeneous or homogeneous presence of Hb variants: two HbC, one HbD, one HbE and HbA2'. One sample was compound heterogeneous for HbS and HbC. On the Minicap Flex Piercing, a minimal overlap between HbC and HbA2 was found.
The authors concluded that as HPLC methods have the advantage of a great precision in detection of a large number of variants, it has the disadvantage of a complex elution pattern that may be difficult to interpret for many routine chemistry laboratories. The Minicap Flex Piercing showed similar analytical performance compared to previous published work using CZE. As for HPLC, CZE gives only a provisional identification of variant hemoglobins, and confirmation by an alternative method based on a different principle is needed. The study was published in the June 2015 issue of the International Journal of Laboratory Hematology.
Related Links:
University Hospital Leuven
Sebia
Bio-Rad Laboratories
Latest Clinical Chem. News
- Urine-Based Test Shows Promise for Autism Screening in Children
- Blood-Based Sensor Detects Early Signs of Alzheimer’s and Parkinson’s
- Liquid Biopsy Biomarkers May Improve Childhood Epilepsy Diagnosis
- Urine-Based Alzheimer’s Test Receives FDA Breakthrough Device Designation
- Fluid Biomarker Improves Diagnosis and Monitoring of Primary CNS Lymphoma
- New CA19-9 Cutoff Value Helps Identify High-Risk Pancreatic Cancer Patients
- Blood-Based Biomarkers Show Promise for Psychosis Risk Prediction
- International Experts Recommend Ending Routine 'Corrected' Calcium Reporting
- Long-Term Data Show PSA Screening Modestly Reduces Prostate Cancer Deaths
- Urine-Based Nanosensor Tracks Lung Cancer and Fibrosis Noninvasively
- FDA-Cleared Assay Enables Comprehensive Automated Testosterone Testing
- CE-Marked Blood Biomarker Test Advances Automated Alzheimer’s Diagnostics
- Blood-Based Alzheimer’s Test Gains CE Mark for Amyloid Pathology Detection
- Noninvasive Urine Test May Support Earlier Diagnosis of Psychiatric Disorders
- At-Home Blood and Cognitive Tests Support Dementia Risk Stratification
- Ultrasensitive Test Detects Key Biomarker of Frontotemporal Dementia Subtype
Channels
Clinical Chemistry
view channel
Urine-Based Test Shows Promise for Autism Screening in Children
Autism spectrum disorder (ASD) is commonly diagnosed through behavioral assessments, which can involve long waits that delay intervention. Earlier identification is linked to better developmental outcomes,... Read more
Liquid Biopsy Biomarkers May Improve Childhood Epilepsy Diagnosis
Childhood epilepsy remains a major neurological disorder with unmet needs for accurate, non-invasive biomarkers, as conventional tests such as electroencephalography and neuroimaging can have limited sensitivity... Read moreMolecular Diagnostics
view channel
Updated Guidance Prioritizes Stool-Based Colorectal Cancer Screening Tests
Colorectal cancer is the second-leading cause of cancer death in the United States and claimed an estimated 55,000 lives in 2026. Incidence is rising among adults younger than 50, even as overall mortality... Read more
Digital PCR Assays Support Surveillance of Bundibugyo Ebolavirus Outbreak
QIAGEN (Venlo, Netherlands) has introduced two custom-designed research-use-only (RUO) QIAcuity dPCR assays to support infectious disease research and surveillance connected to the Bundibugyo ebolavirus outbreak.... Read more
Blood-Based Proteomic Test May Predict Treatment Response in Non-Small Cell Lung Cancer
Lung cancer remains the leading cause of cancer death, with non-small cell lung cancer (NSCLC) accounting for most cases. Treatment decisions are often made without a clear indication of how a patient... Read moreImmunology
view channel
Metabolic Biomarker Distinguishes Latent from Active Tuberculosis and Tracks Treatment Response
Tuberculosis (TB) remains the world’s leading infectious killer, with 10.8 million cases and 1.25 million deaths recorded globally in 2023. Yet many infected individuals never develop active disease, underscoring... Read more
Immune Enzyme Linked to Treatment-Resistant Inflammatory Bowel Disease
Inflammatory bowel disease (IBD) affects nearly 3 million people in the United States and its prevalence continues to rise. Medications that target tumor necrosis factor (TNF)-alpha are widely used, but... Read moreMicrobiology
view channel
Gut Microbiome Signatures Help Identify Risk of IBD Progression
Inflammatory bowel disease (IBD), encompassing Crohn’s disease and ulcerative colitis, is a chronic relapsing inflammatory disorder of the gastrointestinal tract with highly variable outcomes.... Read more
FDA-Cleared Gastrointestinal Panel Detects 24 Pathogen Targets
Clinical guidelines support testing based on patient presentation in suspected gastrointestinal infections, yet available technologies have often forced laboratories to choose between panels that are too... Read morePathology
view channel
AI-Powered Atlas Maps Immune Structures Linked to Cancer Outcomes
Tertiary lymphoid structures are emerging as important indicators of antitumor immunity, but their heterogeneity and spatial context within tumors remain difficult to capture through routine diagnostics.... Read more
AI Tool Extracts Immune Signals from Biopsy to Inform Myeloma Therapy
Multiple myeloma is a bone marrow malignancy in which patients can respond very differently to the same treatments, making initial therapy decisions difficult. Clinicians must choose among options such... Read moreTechnology
view channel
Mailed Screening Kits Help Reduce Colorectal Cancer Screening Gaps
Colorectal cancer screening is a longstanding preventive priority, yet participation and follow-up remain uneven across patient groups. Safety‑net primary care settings often face barriers that limit screening... Read more
Algorithm Panel Aids Liver Fibrosis Assessment and Liver Cancer Surveillance
Chronic liver disease is common and often progresses silently, increasing the risk of cirrhosis and hepatocellular carcinoma when not detected early. With an estimated 1.5 billion people affected worldwide... Read moreIndustry
view channelWerfen and Oxford Nanopore Collaborate on Transplant Assay Development
Werfen (Barcelona, Spain), a global specialized diagnostics company, has announced a strategic collaboration with Oxford Nanopore Technologies (Oxford, UK), which develops nanopore-based sequencing technology,... Read more








